Updated:
LAV Asset Management
Yi Shi founded LAV Asset Management in 2007 to invest exclusively in life sciences, backing biotechs like Zai Lab and Chi-Med from its Hong Kong-Shanghai...
LAV Asset Management
LAV Asset Management started in 2007 as a thesis-driven venture firm purpose-built for healthcare. Founder Yi Shi earned a PhD in biochemistry before moving into investment, and the firm has stayed squarely in life sciences ever since. LAV operates from Hong Kong and Shanghai, a deliberate dual-anchor to cover regulatory and market access gateways in China while maintaining visibility with global pharmaceutical strategics. The firm commits across venture and growth equity, with a portfolio spanning biopharmaceuticals, medical devices, and diagnostics. It entered early-stage opportunities including Zai Lab, a Shanghai- and Cambridge-based biotech that listed on Nasdaq in 2017 and later in Hong Kong. Another holding is Hutchison China MediTech (Chi-Med), which transitioned from a traditional medicine heritage to a commercial-stage oncology innovator listed in London and Hong Kong. LAV's geographic footprint concentrates on China-headquartered companies, but its later-stage portfolio companies often pursue dual listings and global pharma collaboration agreements. LAV manages multiple USD and RMB-denominated funds. The firm has not disclosed its total committed capital or headcount publicly. A recent operational marker came in 2021 when LAV closed LAV Biosciences Fund V at $1.2 billion, its largest vehicle at that date (per the firm, 2021). Adjacent vehicles or philanthropic structures tied to the principals are not publicly documented. The firm maintains a partner-driven investment committee with Shi and co-founder James Zhi anchoring the senior leadership. The firm's structural differentiator is its insistence on a fully dedicated healthcare mandate from a founding team with scientific, rather than purely financial, training. Unlike generalist Asia growth funds that allocate a portion to health, LAV's analysts and partners evaluate targets through a peer-review-informed lens, a posture that gives the firm access to academic spinouts that bypass generalist dollars.
General information
Firm type
Asset Manager
Year founded
2007
AUM
Undisclosed
Location
Region
Asia
Country
Hong Kong
City
Hong Kong
Corporate office
Hong Kong, Hong Kong
Additional offices
Shanghai, China
Principals
Yi Shi
Founder and Managing Partner
James Zhi
Managing Partner
Sector focus
Frequently asked questions
Who runs investment decisions at LAV?
Founder Yi Shi and Managing Partner James Zhi anchor the investment committee. Shi holds a PhD in biochemistry and brings a scientific lens to portfolio construction. The firm keeps its senior partner group small, with investment decisions made by the partnership rather than a single CIO.
Is LAV structured as a family office or does it operate more like a venture firm?
LAV operates as an institutional venture and growth equity manager raising third-party capital, not a family office. It manages USD and RMB-denominated funds from offices in Hong Kong and Shanghai, with limited partners including pension funds, sovereign wealth funds, and fund-of-funds.
What investment stages does LAV typically target?
LAV invests from early-stage venture through crossover and growth equity. The firm can hold positions from company formation through IPO and follow-on rounds. Its portfolio companies often list on Nasdaq or the Hong Kong Exchange, with LAV sometimes maintaining a position post-listing to capture commercial-stage growth.
Which sectors does LAV explicitly avoid?
LAV is exclusively life sciences and healthcare. The firm does not invest in consumer internet, enterprise software, fintech, or any non-healthcare verticals. Within healthcare, its portfolio spans biopharmaceuticals, medical devices, and diagnostics, but it does not pursue healthcare services or provider models outside of the innovation supply chain.
How does LAV source proprietary deal flow?
Academic spinouts and translational science labs form a critical sourcing channel, given the founding team's scientific credentials. LAV also relies on relationships with major pharmaceutical strategics who flag collaboration-ready assets. Its narrow mandate and hands-on board participation give the firm visibility into companies before they run broad auction processes.
Does LAV participate in fund commitments or only direct deals?
LAV deploys capital exclusively through direct equity investments in portfolio companies. The firm does not operate a fund-of-funds program, nor does it allocate to external managers as a core strategy. Its fund vehicles are direct-investment venture and growth equity pools.
What is LAV's known posture on co-investments alongside external GPs?
LAV syndicates with other life sciences specialists and generalist crossover funds on larger growth rounds. The firm does not publicly market a co-investment program, but its participation in consortium deals alongside global healthcare investors is a regular feature of later-stage rounds for its portfolio companies preparing for public listing.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: